世界中医药
文章摘要
引用本文:庞彩苓,宋晓南,王琼.三子养亲汤加减治疗稳定期慢性阻塞性肺疾病[J].世界中医药,2020,(04):.  
三子养亲汤加减治疗稳定期慢性阻塞性肺疾病
Treatment of Stable Chronic Obstructive Pulmonary Disease with Sanzi Yangqin Decoction
投稿时间:2019-01-28  
DOI:10.3969/j.issn.1673-7202.2020.04.025
中文关键词:  稳定期慢性阻塞性肺疾病  三子养亲汤  加减辨治  肺功能  呼吸困难评分  临床症状  生活能力  不良反应
English Keywords:Stable chronic obstructive pulmonary disease  Sanzi Yangxin Decoction  Modified differentiation and treatment  Lung function  Dyspnea score  Clinical symptoms  Living ability  Adverse reactions
基金项目:山东省中医药科技发展计划项目(2012-284)
作者单位
庞彩苓,宋晓南,王琼 山东省潍坊市中医院,潍坊261041 
摘要点击次数: 426
全文下载次数: 0
中文摘要:
      目的:分析三子养亲汤加减治疗稳定期慢性阻塞性肺疾病(COPD)患者的临床疗效,及对患者呼吸功能和改良的英国医学研究委员会呼吸困难评级表(mMRC)评分的影响,探讨其可能的疗效机制,为临床稳定期COPD患者治疗方案的制定提供参考。方法:选取2016年1月至2018年1月潍坊市中医院收治的稳定期COPD患者108例作为研究对象。按照随机数字表法随机分为对照组和观察组,每组54例。2组患者均行稳定期COPD常规综合治疗,观察组加用三子养亲汤加减辨治。2组患者均连续治疗观察8周为1个疗程。比较2组患者治疗前、后主要临床症状积分(咳嗽、神疲乏力、恶风)、肺功能(FFVC、FEV1、FEV1/FVC)、mMRC分级、6分钟步行试验(6MWT)、日常生活能力气短临床评级变化。收集并比较2组患者治疗过程中急性发作次数、药物不良反应发生率。结果:1)完成治疗后,2组患者咳嗽、神疲乏力、恶风临床症状积分均较治疗前下降,且观察组各项症状评分均低于对照组(P<0.05)。2)2组患者完成治疗后肺功能指标FFVC、FEV1、FEV1/FVC均较治疗前提高,且观察组高于对照组(P<0.05)。3)2组患者完成治疗后mMRC0级率、1级率均较治疗前升高,其研究高于对照组,3级率、4级率较治疗前降低,且研究低于对照组(P<0.05);4)2组患者完成治疗后,6MWT距离较治疗前明显提高,且观察组高于对照组(P<0.05);5)2组患者完成治疗日常生活能力气短临床评分0级率、1级率均较治疗前升高,且高于对照组,4级率、5级率较治疗前降低,且低于对照组(P<0.05);6)2组患者治疗过程中未收集到明显药物不良反,均未发生急性发作。结论:三子养亲汤加减治疗稳定期COPD患者,可有效缓解患者临床症状,肺功能,提升患者mMRC评分,综合提升治疗效果,且未增加药物不良反应,具有较高的临床价值。
English Summary:
      To analyze the clinical effects of Sanzi Yangqin Decoction on patients with stable chronic obstructive pulmonary disease(COPD)and its influence on patients' respiratory function and the modified British Medical Research Council Dyspnea Rating Scale(m-MRC)Scores,and to explore its possible therapeutic mechanism,so as to provide reference for the formulation of treatment plan for patients with stable COPD.Methods:A total of 108 patients with COPD who were treated in Weifang Hospital of Traditional Chinese Medicine from January 2016 to January 2018 were selected as the study subjects.According to random number table method,the patients were randomly divided into a control group and a study group with 54 cases in each group.The 2 groups of patients were treated with COPD routine comprehensive treatment in stable stage.The study group was treated with modified Sanzi Yangxin Decoction.The 2 groups of patients were observed for 8 weeks as a course of treatment.The changes of main clinical symptom scores(cough,fatigue,nausea),pulmonary function(FFVC,FEV1,FEV1/FVC),mMRC classification,6-minute walking test(6MWT)and clinical rating of shortness of breath were compared between the 2 groups before and after treatment.The number of acute episodes and the rate of adverse drug reactions were collected and compared between the 2 groups.Results:1)After treatment,the scores of cough,fatigue and cachexia in both groups were lower than those before treatment,and the scores of symptoms in the study group were lower than those in the control group(P<0.05).2)The lung function indexes FFVC,FEV1 and FEV1/FVC of the 2 groups after treatment were all higher than those before treatment,and the study group was higher than that of the control group(P<0.05).3)The grade 0 and grade 1 rates of mMRC in the 2 groups were higher than those before treatment,and the study was higher than that in the control group.The grade 3 and grade 4 rates were lower than those before treatment,and the study was lower than that in the control group(P<0.05).4)After treatment,the distance of 6MWT in the 2 groups was significantly higher than that before treatment,and the study group was higher than that in the control group(P<0.05).5)Both groups of patients completed the treatment of daily life shortness of breath clinical scores of grade 0 and grade 1,which were higher than those before treatment.The study was higher than the control group,and grades 4 and 5 rates were lower than those before treatment.The study was lower than the control(P<0.05).6)No significant adverse drug reactions were collected during treatment in both groups,and no acute episode occurred.Conclusion:Modified Sanzi Yangqin Decoction can effectively relieve the clinical symptoms and lung function of patients with stable COPD,improve the mMRC score of patients,and comprehensively improve the therapeutic effects,without increasing adverse drug reactions,so it has high clinical value.
查看全文  查看/发表评论  下载PDF阅读器